13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-10, with 19 holding rows worth $222,441,000.
- Accession
- 0001567619-22-019570
- Filer
- CIK 1440771
- Filed
- 2022-11-10
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2022
A holdings report, 19 entries on the cover page, a total value of $222,441,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $222,441,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMRYT PHARMA LTD - SPNR ADR | 03217L106 | COMMON EQUITY | 6,227,733 | $43,096,000 | thousands by filing date | |
| QUIDELORTHO CORP COM | 219798105 | Stock | 501,633 | $35,857,000 | thousands by filing date | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 5,669,388 | $32,996,000 | thousands by filing date | |
| XERIS BIOPHARMA HOLDINGS INC | 98422E103 | COM | 12,928,168 | $20,168,000 | thousands by filing date | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 2,832,631 | $15,608,000 | thousands by filing date | |
| ADMA BIOLOGICS INC | 000899104 | COM | 5,000,000 | $12,150,000 | thousands by filing date | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 1,124,220 | $9,354,000 | thousands by filing date | |
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 8,547,965 | $9,317,000 | thousands by filing date | |
| LIGAND PHARMACEUTICALS INC | 53220K504 | COM NEW | 99,562 | $8,573,000 | thousands by filing date | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 2,973,205 | $8,147,000 | thousands by filing date | |
| OPTINOSE INC | 68404V100 | COM | 2,000,000 | $7,320,000 | thousands by filing date | |
| AFFIMED N V | N01045108 | COM | 1,979,828 | $4,078,000 | thousands by filing date | |
| EXAGEN INC | 30068X103 | COM | 1,265,373 | $3,429,000 | thousands by filing date | |
| CONFORMIS INC | 20717E101 | COM | 17,304,350 | $3,309,000 | thousands by filing date | |
| OVID THERAPEUTICS INC | 690469101 | COMMON STOCK | 1,540,671 | $2,835,000 | thousands by filing date | |
| ATYR PHARMA INC | 002120202 | COM NEW | 600,980 | $1,803,000 | thousands by filing date | |
| OPIANT PHARMACEUTICALS INC | 683750103 | COM | 152,278 | $1,637,000 | thousands by filing date | |
| EVOLUS INC | 30052C107 | COM | 200,000 | $1,610,000 | thousands by filing date | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 64,459 | $1,154,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001567619-22-019570 | this filing | 2022-11-10 | acceptance time not in the bulk data set |